Stay updated with breaking news from Christopherw Ryan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.
However, the drug did show benefit in a subgroup at highest risk of recurrence after nephrectomy
Christopher W. Ryan, MD, discusses the role of adjuvant therapy for patients with renal cell carcinoma.
Christopher W. Ryan, MD, professor of medicine School of Medicine at the Oregon Health & Science University, discusses the evolution of therapeutic treatment approaches across the management treatment landscape of renal cell carcinoma.
Christopher W. Ryan, MD, discusses the implications of updated findings from the phase 3 JAVELIN Bladder 100 trial in patients with locally advanced or metastatic urothelial cancer.